Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If an iHubber prompted BIEL to fix their website that’s wonderful. I for one appreciate any thoughtful criticism, it’s just as valid as enthusiasm for the great things that have happened recently.
Let’s just watch the back and forth, we would want newcomers to the board to get an every-opinion-is-welcome vibe here and not get a dysfunctional view of the iHub community. On balance, I would assume that any newcomer can piece things together by looking at the totality of this board, checking their new and improved website, and doing their own DD (including FDA and SEC material) to conclude that there is a ton of value here! Just my opinion.
Have watched this since 2009 and am just enjoying the ride.
Yes, at .07!
That’s what I was remembering. Maybe that lends weight to the theory that there is a large investor out there buying up shares.
Not sure if MAXM is new. They are
.0001 on the bid and .07 on the ask. Not sure how meaningful that info is, I’m not a MM expert. Was there some speculation that we have seen new, serious MMs who are trying to help major buyers accumulate? Or did I imagine that.
Level II looks solid, a line of .38 asks. We may end up 11.8 % for the day. If we hold that tomorrow, away we go into the 40s. Not a technical trader, but when we cross .005 I wouldn’t be surprised to see a sustained wave of buys coming in. The closer we get to a penny the more deep pockets are likely to come in. I’m sure there are plenty of investors who don’t have the stomach to buy something less than a cent.
Hoping for a steady, sustained run like we had in April.
It sounds like we might be able to expect big things by the end of August (full FDA clearance and Dr. Scholl’s). I can be patient for that.
In the meantime, UK sales, including B. Braun’s use of patches in surgical kits should result in 2018 sales several times the size of 2017. That’s without any extra dealmaking, FDA action, or any other windfall.
In other words, we are on autopilot as sales numbers come in and get reported. The next quarter will include NHS reimbursement and the one after that will likely include the B. Braun increase.
By the time we have the first three quarters of increased earnings reported in November/early December, things will look much brighter based on numbers alone.
Add in FDA clearance, and Dr. Scholl’s and .18 isn’t that crazy for December. That’s a $3.6 bln market cap. If I’m big pharm, that’s pocket change for the cost of coopting a big disrupter to their bottom line.
And if I’m a betting person, BIEL’s a contender for this FDA pain relief contest. Wouldn’t that be a great PR! Maybe we’ll place or show (land in top 3) and be mentioned in a good article.
Multiple Y over Y Increased sales AND full FDA = Exacta.
Multiple Y over Y Increased sales AND full FDA AND Dr. Scholl’s = Trifecta.
Huge payout for a .0006-8 ticket (the cost basis for many of us).
Unless I’m mistaken the new product code is PQY:
https://www.accessdata.fda.gov/cdrh_docs/pdf15/K152432.pdf
This is the product code in their latest approval. The ILX code leads one to the old Actiband approval letter.
The creation of the new category is a great thing, in my opinion, not trying to be negative, but I don’t know that it’s productive to check the old ILX status. And we know from past experience that those webpage update dates are not necessarily meaningful.
IMO we will know from Keith, PRs, and 510k approval page when we get substantial news rather than the product code pages.
Simpson, you out there? As our resident FDA expert let me know if this makes sense.
No offense to anyone, I have posted about the feeling of inevitability here and the presubmission approval for broader clearance is huge! It sounds like a matter of weeks (at the risk of sounding like that infamous 2009 announcement) or a couple of months tops.
Based on Keith tweeting on his way to the meeting, I think we can expect a relatively quick update after the meeting. Within a day or two. Hopefully we get a good idea of how long it will take the FDA, or a confirmation that it’s approved and there are boxes that need to be checked (and redesigned).
My favorite post. Maybe doubters just have normalcy bias. This won’t happen because it’s new and has never happened before. But every new technology is doubted in the beginning.
Share structure, price, SEC, and up and down history for the last 9 years contribute to valid doubts, but in my opinion this may all be swept away as BIEL lands a major partnership (sneaking their way into shelves with the help of the Dr), finally gets major publicity, and all the while UK money flows in.
To go from never being profitable to millions of dollars in profit seemingly overnight will get lots of major investor attention. I believe Keith when he says that they get calls all the time from companies asking to work with them.
I agree that it should take far less time. I don’t think they will need to resubmit or formally edit the 510k. It sounds like they are very close. But based past history, it’s unlikely they will get full approval the same day, or even the same week.
Kushner’s in charge of solving the opiate epidemic, I have complete faith in him.
Seriously though, in my opinion this is going to come out the right way, but it’s going to happen on the FDAs timeline. Not 6 months, but could be as long as 6 weeks. I think in the short term, we can hope for a positive tweet, email, or update on the meeting(s) but not a whole lot more. I’d love to be proved wrong though.
I’ll admit I do find myself re-reading the SP projections. .28 may sound crazy, but with 5 mm Actipatch users and a P/E or 60 (based on $7 profit per device) its not nearly as crazy as it sounds.
I hear God’s plan playing in my head after rereading it.
In my opinion, I would not give any one penny stock expert’s opinion more weight than what we know to be fact. We know Rory has a track record of success and that he has landed major deals. This is a real product with real revenue and has made a major deal with a Fortune 50 company.
Upon information and belief, TS has some early success and has run money for funds and given a lot of expert advice. I don’t doubt that he’s had success, but a trader can be wrong more often than right and still make money. There’s no compelling reason to say he’s right here. Just curious, did he disclose a short position? Maybe our new sheriff will know.
Card players out there know pot-odds calculations mean you take worthwhile risks if the potential rewards justify them. You can be wrong more often than your right and still make money.
If this stock ends up as a case study of pump and dump vs legit company, in hindsight, in my opinion students will easily be able to point out the myriad reasons why this is the real thing.
This is getting fun to watch. I feel like our baby’s all grown up and is ready to spread its wings and leave the nest.
We just matched a 3 year high
In hindsight, the immediate effect may have been negative. But isn’t it possible that many shorts will be lured in before a huge upward movement after Oracle PR comes out? I’m not sure Oracle cares too much about our drama here as long as we get them results.
Hold it together people, listen to Solid as Rock (Fusz, inc.). You can’t keep a good man down ... things get better when they thought it would be worse.
But Al, there’s a new sheriff in town. Swamps being drained as we speak.
Seriously though, OTC is the Wild West, far from being transparent. A CEO from a different OTC gave a very similar PR about shorting a week or two before Rory. I’m not sure what can be done exactly. I’ve seen this before, but in my limited experience, real, concrete products and revenue will win out over shenanigans.
I have faith in FUSZ, think Rory’s doing a great job. Oracle people, Oracle! If your timeline is at least six months, I think this all comes out in the wash.
Bid 21 ask 23
Only 19s and 20s on the level 2 ask ...
Nick Foles (Keith) just took us all the way down the field on our opening drive to score a TD. Shocking the Patriots.
It is a wonderful way to circumvent the barrier to enter the big stores - partner and piggy back on an existing product that already has prime shelf space. Brilliant really.
There’s a new sense of inevitability here. The only major dip I see is if we get a bad outcome from the Lucia case and have to pay up. Even then, we now have enough money to pay the fine. Pay the fine and potentially have to reduce the role of the Whelans with Keith taking over.
But I think it’s 50/50 on the outcome.
That’s a very excellent guess given the new name of the insole product and discussion of the Doctor going back years. It also seems more attainable at the moment than the big box stores given the annual planograms and the likelihood that we were unsuccessful back in October.
“Significant deal just on the horizon”!
The company is immensely proud of their team for getting their concept through to the National Health Service (NHS) in the UK. In addition to successes here, the company is hoping to utilize their overseas success by applying data to their US-based efforts.
There are some great potential partnerships currently being discussed at BioElectronics, with the closing of a significant deal just on the horizon.
(Quote from Keith in the Nasdaq new update)
Thanks pears. Some quick math:
- An article about the acquisition put Grapeshot’s previous valuation at $56m.
- Oracle bought them for $300-400m.
- Putting the actual price at $350m means a multiplier of 6.25.
- 6.25 x fusz’s current price of around 2 puts us at $12.50 a share.
- Crazy? I don’t think so. I think Rory might actually balk at that price and hold out for more. As a small shareholder, I’m fine cashing out and selling the equivalent of Oracle shares at $12.50. That’s a nice profit from my entry point and for anyone else, even if you bought at the absolute high.
- Rory put this at $7 minimum with Oracle revenue, so I don’t see him selling for any less.
- just my opinion, but I think these numbers are worth considering when you look at possible price movements over the next several months.
As a relative new investor, but who still got in at .55, I’m not worried in the slightest about the last two days. Whether it’s MMs playing games or some early creditor exercising their warrants, IMO it will have zero effect on the long term (even six month outlook) on this stock. I think you are fine even if you entered at 2.50 or 3.00. Maybe people were expecting a huge PR and they didn’t get it, I have no idea.
IMO, we are looking at $7-10 minimum by August. I see a lot of new names and that’s great, but everyone needs to just relax and take a breath. 2 red days will be meaningless just 30 or 60 days into the future of this company. Just my opinion.
Perfect, thanks. Sorry for missing that. The potential for future growth with NHS is staggering. The only challenge now is waiting the many months for Q2 to come him. Here’s hoping we get some sort of PR within the next month or so with some preliminary numbers. Transparency has historically not been one of this company’s strengths, but I do appreciate the effort they put into the recent shareholder letter. No complaining here, glad to be in.
I don’t think you can use 24 hours, maybe 12 hours. People won’t buy at the same rate during the middle of the night, unless I missed something in your posts that accounted for this.
You called it. I would just add the additional benefit of accelerated profitability in additional to confidence.
Not an expert either, but I would say this is a very good thing. This means that Rory’s appropriate, but substantial salary will not longer be an ongoing operating cost. This makes profitability that much closer and I believe part of the reason is that it could accelerate uplisting and the attraction of institutional investors because it strengthens their balance sheet and quarterly reports. With tens of thousands of potential subscribers and the elimination of Rory’s salary, IMO profitability is greatly accelerated.
Yes, he could sell his shares someday, but they are restricted so he won’t be dropping them anytime soon. He took his last company into the end zone, so I don’t see why he would settle for a field goal here and sell early. Sure, the price is after a dip, but hey, he’s a smart businessman, more power to him. IMO we will all thank him for this move in the near to medium future.
Gurus from Burton Malkiel (Random Walk Down Wall Street) to Warren Buffett would tell you that technical analysis is not accurate and is not supported by any statistically significant study. However, it’s also possible that enough people believe in it and follow it that it becomes real - have their stop loss orders set to certain technical milestones and buy based on other indications - that it becomes a factor in stock price, especially OTCs with lower illiquidity. Maybe self-fulfilling prophecy is too strong, but there’s something to be said for Soros’s reflexivity theory that things like a credit ratings downgrade of a company’s creditworthiness or an analyst report has a real effect whether it was based in “reality” or not. Perception becomes reality, SP drops. Others see it as a buying opportunity and so on ...
I personally like the “head and shoulders” pattern which seems to occur with regularity, although I observe it in hindsight and never trade on it.
The biggest factors here which IMO push us to $2-4 are the Oracle deal and the seemingly endless lineup of products and revenue. Plus Rory’s done this before with another company and there’s every indication he’s doing it again. Whether that’s ride this through uplisting to $4 + or be bought out and cash out, I don’t know.
I’m just enjoying the ride. Thanks to pears for mentioning this on another board.
Easy on pears ppl, we can agree to disagree. Classic financial advice is don’t sink too much of your money or 401k into your employer’s stock because you risk losing your job and your investment if things go wrong (Enron).
Unless ... you’re the CEO or other C-level exec because it shows personal confidence in the company and is a strategic move to increase investor confidence.
Pears is suggesting a classic strategic move.
That being said, my personal opinion is that we are fine and Rory’s doing an excellent job as is without public purchases. If the stock was tanking, then I might agree.
But let’s welcome differences of opinion it’s healthy debate.
I’m I interpreting this correctly, that a huge 100K block offered by MM CANT moved up to .70 from a lower price, so we have room to run up - the sell blocks lower prices are much smaller?
But I have seen, at least on other stocks, 1000 blocks that sit on the sell side forever, like they are continuously being replaced.
With blue chips it’s a usually an explicit one year price target, maybe that’s too much to ask of the people who cover OTCs. In time, with uplisting, I’m sure we’ll have major shops covering this. Assuming it’s not bought out, that is.
I took that one back, another poster keyed me in to the real definition. Loose use of a term of art by me.
I stand corrected, thanks for the info.
Under normal circumstances with a non OTC stock, no, I would never expect a stock to reach a price target within a week. The way that this has moved and the way it looked late last week, it seemed probable. I got carried away there.
I believe the CEO said the pharmacy acquisition would close in the second quarter. IMO, the announcement of that closing is a decent milestone and timing for this to hit .35.
Well we didn’t hit the new price target this week of .35, so much for that. But in my opinion this is way oversold , as others have said, when Feb numbers and then quarterly financials showing q over q growth come out, this will bounce up. The Uptick host had a pps value of .50 on this.